Pharmanutra Valuation
Is 761 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 761 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 761 (€53.5) is trading above our estimate of fair value (€42.63)
Significantly Below Fair Value: 761 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 761?
Key metric: As 761 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 761's PE Ratio? | |
|---|---|
| PE Ratio | 31.8x |
| Earnings | €16.27m |
| Market Cap | €516.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.6x |
| Enterprise Value/EBITDA | 17.2x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does 761's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.4x | ||
BEI Beiersdorf | 37.3x | 12.7% | €27.6b |
7806 MTG | 25.8x | 10.8% | JP¥74.5b |
W7L Warpaint London | 24.7x | 11.8% | UK£423.7m |
MARICO Marico Bangladesh | 13.7x | n/a | ৳72.8b |
761 Pharmanutra | 31.8x | 18.5% | €516.9m |
Price-To-Earnings vs Peers: 761 is expensive based on its Price-To-Earnings Ratio (31.8x) compared to the peer average (25.4x).
Price to Earnings Ratio vs Industry
How does 761's PE Ratio compare vs other companies in the European Personal Products Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 761 is expensive based on its Price-To-Earnings Ratio (31.8x) compared to the European Personal Products industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is 761's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.8x |
| Fair PE Ratio | 18.4x |
Price-To-Earnings vs Fair Ratio: 761 is expensive based on its Price-To-Earnings Ratio (31.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €53.50 | €84.33 +57.6% | 5.3% | €88.00 | €78.00 | n/a | 3 |
| Nov ’25 | €53.90 | €81.33 +50.9% | 5.1% | €86.00 | €76.00 | n/a | 3 |
| Oct ’25 | €56.70 | €81.33 +43.4% | 5.1% | €86.00 | €76.00 | n/a | 3 |
| Sep ’25 | €53.80 | €80.33 +49.3% | 5.2% | €86.00 | €76.00 | n/a | 3 |
| Aug ’25 | €46.20 | €80.33 +73.9% | 5.2% | €86.00 | €76.00 | n/a | 3 |
| Jul ’25 | €47.65 | €80.33 +68.6% | 5.2% | €86.00 | €76.00 | n/a | 3 |
| Jun ’25 | €48.30 | €80.33 +66.3% | 5.2% | €86.00 | €76.00 | n/a | 3 |
| May ’25 | €53.60 | €80.67 +50.5% | 4.8% | €86.00 | €77.00 | n/a | 3 |
| Apr ’25 | €56.60 | €80.67 +42.5% | 4.8% | €86.00 | €77.00 | n/a | 3 |
| Mar ’25 | €58.80 | €79.33 +34.9% | 6.0% | €86.00 | €75.00 | n/a | 3 |
| Feb ’25 | €61.10 | €79.33 +29.8% | 6.0% | €86.00 | €75.00 | n/a | 3 |
| Jan ’25 | €56.10 | €78.67 +40.2% | 6.6% | €86.00 | €75.00 | n/a | 3 |
| Dec ’24 | €50.70 | €78.67 +55.2% | 6.6% | €86.00 | €75.00 | n/a | 3 |
| Nov ’24 | €49.50 | €83.33 +68.4% | 5.4% | €87.00 | €77.00 | €53.90 | 3 |
| Oct ’24 | €48.75 | €83.33 +70.9% | 5.4% | €87.00 | €77.00 | €56.70 | 3 |
| Sep ’24 | €54.60 | €82.67 +51.4% | 6.6% | €87.00 | €75.00 | €53.80 | 3 |
| Aug ’24 | €57.50 | €82.67 +43.8% | 6.6% | €87.00 | €75.00 | €46.20 | 3 |
| Jul ’24 | €60.80 | €82.67 +36.0% | 6.6% | €87.00 | €75.00 | €47.65 | 3 |
| Jun ’24 | €58.10 | €82.67 +42.3% | 6.6% | €87.00 | €75.00 | €48.30 | 3 |
| May ’24 | €50.50 | €83.00 +64.4% | 4.3% | €86.00 | €78.00 | €53.60 | 3 |
| Apr ’24 | €55.60 | €83.00 +49.3% | 4.3% | €86.00 | €78.00 | €56.60 | 3 |
| Mar ’24 | €59.80 | €83.33 +39.4% | 3.7% | €86.00 | €79.00 | €58.80 | 3 |
| Feb ’24 | €58.80 | €83.33 +41.7% | 3.7% | €86.00 | €79.00 | €61.10 | 3 |
| Jan ’24 | €62.80 | €83.33 +32.7% | 3.7% | €86.00 | €79.00 | €56.10 | 3 |
| Dec ’23 | €62.20 | €81.25 +30.6% | 5.5% | €86.00 | €75.00 | €50.70 | 4 |
| Nov ’23 | €68.20 | €81.50 +19.5% | 6.9% | €88.00 | €75.00 | €49.50 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Cheerwin Group
HK$2.5b
An investment holding company, manufactures and trades household insecticides and repellents, household cleaning, air care, personal care, pets and pet products, and other products in the People’s Republic of China.
1RQ
HK$0.21
7D
-2.8%
1Y
26.5%
McBride
UK£182.8m
Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.
10W
UK£1.21
7D
6.1%
1Y
80.6%
Revolution Beauty Group
UK£39.3m
Engages in the development, production, wholesale, and retail of beauty products in the United Kingdom, the United States, and internationally.
8UA
UK£0.15
7D
-7.4%
1Y
-45.3%